Generation Bio Co. logo
Generation Bio Co. GBIO

Quarterly report 2025-Q3
added 11-05-2025

report update icon

Generation Bio Co. Market Cap 2011-2026 | GBIO

As of April 07, 2026 Generation Bio Co. has a market cap of $ 344 M


Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]

Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.

This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.

Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.

Annual Market Cap Generation Bio Co.

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
179 M 255 M 288 M 952 M - - - - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
952 M 179 M 418 M

References

  1. Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.

Market Cap of other stocks in the Biotechnology industry

Issuer Market Cap Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
315 M - 2.43 % $ 254 M germanyGermany
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
895 M $ 3.6 1.34 % $ 8.66 B australiaAustralia
Aytu BioScience Aytu BioScience
AYTU
15.8 M $ 2.66 - $ 16.7 M usaUSA
BioNTech SE BioNTech SE
BNTX
62.9 B $ 91.28 - $ 27.2 B germanyGermany
I-Mab I-Mab
IMAB
127 M - - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
33.6 B - - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
168 B - 2.54 % $ 160 B franceFrance
Burford Capital Limited Burford Capital Limited
BUR
2.09 B $ 4.48 - $ 736 M britainBritain
Biophytis SA Biophytis SA
BPTS
549 M - -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
496 M $ 1.85 - $ 353 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
79 M - -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
28.9 M - -1.52 % $ 24.7 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
16.7 M - -24.86 % $ 820 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
226 M $ 1.67 - $ 196 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
2.04 B $ 31.37 - $ 2.08 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
28.2 M $ 0.44 - $ 5.04 M israelIsrael
Advaxis Advaxis
ADXS
1.87 M - -9.65 % $ 45.9 M usaUSA
Adverum Biotechnologies Adverum Biotechnologies
ADVM
76.4 M - - $ 86.2 M usaUSA
CNS Pharmaceuticals CNS Pharmaceuticals
CNSP
1.06 M $ 2.32 - $ 1.03 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
2.83 B - - - russiaRussia
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
3.04 B $ 24.98 - $ 3.05 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
127 M $ 10.14 - $ 135 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
116 M $ 1.58 - $ 106 M usaUSA
Curis Curis
CRIS
9.48 M $ 0.53 - $ 6.98 M usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
4.11 B $ 37.7 - $ 3.55 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
4.39 B $ 49.15 - $ 4.42 B schweizSchweiz
Aeterna Zentaris Aeterna Zentaris
AEZS
41.4 M - 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
14.1 K - -10.17 % $ 12.2 K usaUSA
CytomX Therapeutics CytomX Therapeutics
CTMX
931 M $ 4.4 - $ 607 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
24.2 M $ 0.86 - $ 5.79 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
724 M - - $ 1.01 B usaUSA
Cue Biopharma Cue Biopharma
CUE
29.4 M $ 0.18 - $ 17.1 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
32.8 M - - $ 26.5 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
2.82 B $ 20.36 - $ 2.84 B franceFrance
AIkido Pharma AIkido Pharma
AIKI
19.6 M - 1.93 % $ 17.4 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
2.32 M - -45.71 % $ 1.2 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
3.04 B $ 19.38 - $ 3.19 B usaUSA
Dyadic International Dyadic International
DYAI
31.5 M $ 0.87 -2.8 % $ 31.5 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
3.25 B - - $ 3.67 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
3.53 B - - $ 867 M germanyGermany
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
8.08 B $ 3.54 - $ 238 B britainBritain
Akouos Akouos
AKUS
172 M - 0.23 % $ 488 M usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
30.6 M $ 1.19 - $ 55.5 M israelIsrael
Equillium Equillium
EQ
118 M $ 2.01 - $ 115 M usaUSA
Allakos Allakos
ALLK
114 M - - $ 28.6 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
71.4 M - 3.16 % $ 1.9 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
40.8 B $ 330.34 - $ 43.3 B usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
269 M - - $ 2.17 B usaUSA
Fate Therapeutics Fate Therapeutics
FATE
187 M $ 1.19 - $ 141 M usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
38.2 M - 10.36 % $ 9.8 M usaUSA